Clinical Trial Update: Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod [Phase 4]

View source ↗

Summary

Phase 4 clinical trial in elderly patients with generalized myasthenia gravis evaluating whether efgartigimod can enable corticosteroid-sparing therapy when giv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Myasthenia Gravis, Generalized | Phase 4 | Status: RECRUITING